Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Actinium Pharmaceuticals Inc (ATNM)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Actinium Pharmaceuticals's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
5.600 +0.180    +3.32%
25/01 - Closed. Currency in USD ( Disclaimer )
After Hours
5.680
+0.080
+1.429%
1:00:00 - Real-time Data
  • Volume: 66,087
  • Bid/Ask: 5.020 / 5.680
  • Day's Range: 5.320 - 5.690
Type:  Equity
Market:  United States
ISIN:  US00507W2061 
CUSIP:  00507W206
Actinium Pharmaceuticals 5.600 +0.180 +3.32%
IndustryBiotechnology
SectorHealthcare
Employees

32

Equity Type

ORD

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on Antibody Radiation-Conjugates (ARCs), which combine the targeting ability of antibodies with the cell-killing ability of radiation. Its clinical programs are focused on two primary areas: targeted conditioning prior to bone marrow transplant, adoptive cell or gene therapies and therapeutics, in combination with other therapeutic modalities. Its clinical pipeline is focused on ARCs targeting the antigens CD45 and CD33, both of which are expressed in multiple hematologic cancers. Its lead CD45-targeted conditioning product candidate, Iomab-B, via the monoclonal antibody BC8, targets CD45, an antigen expressed on leukemia and lymphoma cancer cells, B cells and stem cells. Its CD33 program is evaluating the clinical utility of Actimab-A, an ARC consisting of the anti-CD33 mAb lintuzumab linked to the potent alpha-emitting radioisotope Actinium-225 (Ac-225).

Contact Information

Top Executives

Name Age Since Title
Hillard M. Lazarus - 2014 Member of Scientific Advisory Board
Sergio Giralt - 2014 Member of Scientific Advisory Board
Richard M. Stone - 2017 Member of Scientific Advisory Board
Richard Wahl - - Member of Clinical Advisory Board
Jeffrey W. Chell 67 2018 Independent Director
Richard I. Steinhart 64 2013 Independent Director
M. Yair Levy - 2014 Member of Scientific Advisory Board
Ajit S. Shetty 74 2017 Independent Director
Alexander Perl - - Member of Clinical Advisory Board
John M. Pagel - - Chairman of Scientific Advisory Board & Member of Clinical Advisory Board
David A. Scheinberg 65 - Member of Clinical Advisory Board
Sandesh C. Seth 57 2012 Chairman & CEO
Joseph G. Jurcic - - Chairman of Clinical Advisory Board
Elihu H. Estey - - Member of Clinical Advisory Board
Franklin Wong - 2018 Members of Nuclear Medicine Clinical Advisory Board
Hagop M. Kantarjian - - Member of Clinical Advisory Board
Richard E. Champlin - 2014 Member of Scientific Advisory Board
Michael Yu - 2018 Members of Nuclear Medicine Clinical Advisory Board
Dan Pryma - 2018 Members of Nuclear Medicine Clinical Advisory Board
Johannes Czernin - 2018 Members of Nuclear Medicine Clinical Advisory Board
Ghassan El-Haddad - 2018 Members of Nuclear Medicine Clinical Advisory Board
David Colcher - 2018 Members of Nuclear Medicine Clinical Advisory Board
C. David Nicholson 66 2008 Lead Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ATNM Comments

Write your thoughts about Actinium Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email